Source:http://linkedlifedata.com/resource/pubmed/id/11314047
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2001-4-23
|
| pubmed:abstractText |
In many human cancers, the INK4A locus is frequently mutated by homozygous deletions. By alternative splicing this locus encodes two non-related tumor suppressor genes, p16(INK4A) and p14(ARF) (p19(ARF) in mice), which regulate cell cycle and cell survival in the retinoblastoma protein (pRb) and p53 pathways, respectively. In mice, the role of p16(INK4A) as the critical tumor suppressor gene at the INK4A locus was challenged when it was found that p19(ARF) only knock-out mice developed tumors, including gliomas. We have analysed the genetic status of the INK4A locus in 105 primary gliomas using both microsatellite mapping (MSM) and quantitative real-time PCR (QRT-PCR). Comparison of the results of the two methods revealed agreement in 67% of the tumors examined. In discordant cases, fluorescence in situ hybridization (FISH) analysis was always found to support QRT-PCR classification. Direct assessment of p14(ARF) exon 1beta, p16(INK4A) exon 1alpha and exon 2 by QRT-PCR revealed 43 (41%) homozygous and eight (7%) hemizygous deletions at the INK4A locus. In 49 (47%) gliomas, both alleles were retained. In addition, QRT-PCR, but not MSM, detected hyperploidy in five (5%) tumors. Deletion of p14(ARF) was always associated with co-deletion of p16(INK4A) and increased in frequency upon progression from low to high grade gliomas. Shorter survival was associated with homozygous deletions of INK4A in the subgroup of glioblastoma patients older than 50 years of age (P=0.025, Anova test single factor, alpha=0.05).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0950-9232
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1103-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11314047-Chromosome Mapping,
pubmed-meshheading:11314047-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:11314047-DNA Mutational Analysis,
pubmed-meshheading:11314047-DNA Primers,
pubmed-meshheading:11314047-Gene Deletion,
pubmed-meshheading:11314047-Gene Expression,
pubmed-meshheading:11314047-Glioma,
pubmed-meshheading:11314047-Homozygote,
pubmed-meshheading:11314047-Humans,
pubmed-meshheading:11314047-In Situ Hybridization, Fluorescence,
pubmed-meshheading:11314047-Microsatellite Repeats,
pubmed-meshheading:11314047-Middle Aged,
pubmed-meshheading:11314047-Polymerase Chain Reaction,
pubmed-meshheading:11314047-Proteins,
pubmed-meshheading:11314047-Survival Analysis,
pubmed-meshheading:11314047-Tumor Cells, Cultured,
pubmed-meshheading:11314047-Tumor Suppressor Protein p14ARF
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
|
| pubmed:affiliation |
Molecular Neuro-Oncology, Department of Research, University Hospital, Schanzenstrasse 46, 4031 Basel, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|